Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R46 | P59540 | 6/20 | 0.38 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.38 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24778956 | 1.00 | TAS2R46 (0.38) | TAS2R46TAS2R31TAS2R10CYP19A1SMN1; SMN2 | |
| SCHEMBL21673032 | 1.00 | TAS2R46 (0.38) | TAS2R46TAS2R31TAS2R10CYP19A1SMN1; SMN2 | |
| SCHEMBL21673028 | 0.83 | TAS2R31 (0.35) | TAS2R46TAS2R31TAS2R10CYP19A1MAPK1 | |
| SCHEMBL21673015 | 0.82 | TAS2R31 (0.34) | TAS2R46TAS2R31TAS2R10CYP19A1MAPK1 | |
| SCHEMBL21673018 | 0.73 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL21673020 | 0.73 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL21643648 | 0.73 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL12831177 | 0.63 | — | — | |
| SCHEMBL12831179 | 0.63 | — | — | |
| SCHEMBL12831619 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814396-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814396-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814396-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11518770-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2022-12-06 | — | — | US | disclosed |
| US-11518770-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2020033286-A1 | NOVEL SESQUITERPENOID ANALOGS | PURDUE RESEARCH FOUNDATION (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20200040000-A1 | NOVEL SESQUITERPENOID ANALOGS | PURDUE RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814396-B2 | Sesquiterpenoid analogs | POLE3, DUSP3, STK3 | TAS2R46 4226/4885TAS2R31 4524/4885TAS2R10 4621/4885 |
| US-11518770-B2 | Sesquiterpenoid analogs | POLE3, DUSP3, STK3 | TAS2R46 4226/4885TAS2R31 4524/4885TAS2R10 4621/4885 |
| US-20200040000-A1 | NOVEL SESQUITERPENOID ANALOGS | POLE3, DUSP3, TP53 | TAS2R46 4147/4885TAS2R31 4484/4885TAS2R10 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.